First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

<h4>Background</h4>Current therapies for cutaneous leishmaniasis are limited by poor efficacy, long-term course of treatment, and the development of resistance. We evaluated if pentavalent antimony (an anti-parasitic drug) combined with imiquimod (an immunomodulator) was more effective t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cesar Miranda-Verastegui, Gianfranco Tulliano, Theresa W Gyorkos, Wessmark Calderon, Elham Rahme, Brian Ward, Maria Cruz, Alejandro Llanos-Cuentas, Greg Matlashewski
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2009
Materias:
Acceso en línea:https://doaj.org/article/506f33e49e7548ba8ca415edae800b2e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!